CDX2 and colorectal carcinoma: Of potential clinical relevance, we show that patients with stage IV CRC and CDX2‐negative tumors have a median survival of 6.7 months as compared to 23.5 months for patients with CDX2‐positive tumors, suggesting that loss of CDX2 can be a useful biomarker to identify patients with limited benefit from surgery.